Physician profile
Ann Ding
NPI 1376034363
$1,443.32
in general payments reported to CMS, 2019-2025
22 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $169 · 2024: $754 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $350.34 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $153.93 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.70 | 2023-2024 | Ofev, Jardiance, Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $82.61 | 2023-2024 | Eliquis |
| Pfizer INC. | $80.18 | 2024-2025 | |
| Novo Nordisk INC | $73.81 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $71.06 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $68.17 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $52.13 | 2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Harmony Biosciences LLC | $48.37 | 2024 | |
| Amgen INC. | $48.13 | 2025 | Evenity |
| Mylan Specialty L.P. | $37.60 | 2023-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.32 | 2023-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $31.02 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Philips North America LLC | $27.03 | 2023-2025 | Vest Therapy Und |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.20 | 2024 | |
| Grifols USA, LLC | $24.11 | 2024 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $20.60 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.50 | 2025 | |
| Cranial Technologies, INC | $17.31 | 2024 | Doc Band |
| Seqirus USA INC | $17.27 | 2025 | Fluad, Flucelvax |
| Xeris Pharmaceuticals, INC. | $15.93 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.